Immunovia AB (OSTO:IMMNOV)
kr 0.618 -0.01 (-1.59%) Market Cap: 104.88 Mil Enterprise Value: 76.83 Mil PE Ratio: 0 PB Ratio: 2.91 GF Score: 44/100

Q4 2020 Immunovia AB (publ) Earnings Call Transcript

Feb 17, 2021 / 03:30PM GMT
Release Date Price: kr58.18 (+3.95%)
Operator

Welcome to the Immunovia Q4 Conference Call. (Operator Instructions)

Today, I'm pleased to present the CEO, Patrik Dahlen. Please, begin the meeting.

Patrik Dahlen;publ;CEO
Immunovia AB

()-

Thank you, and good afternoon, everyone. Thank you for joining us today, and thank you for your continued interest in Immunovia. My name is Patrik Dahlen. I am the CEO of Immunovia and I will be presenting the full-year 2020 and quarter 4 results for Immunovia. Next page, Page 2.

Here, you can read our disclaimers and forward-looking statements, and I do encourage you to read these at your leisure. Next page, please, Page 3.

Today's agenda is as follows. I will start by discussing the importance of early detection of pancreatic cancer. Second, I will give you a summary of the full year 2020 and the quarter 4 highlights. Under this agenda point, I will discuss the status where we are right now with introduction of the IMMray PanCan-d test and the road to reimbursement.

I will then briefly touch upon our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot